Tradestie Institutional Equity Comparison Engine · Market Close Apr 22, 2026

VTYX vs DAWN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Captures Overall Composite Edge (50.4 HOLD vs 58.3 HOLD), While DAWN Leads 3–2 on Growth & Valuation Pillars

VTYX Overall Winner 6-Pillar Tally: VTYX 2 – 3 DAWN (1 Tie) Matrix Metrics: VTYX 2 – 6 DAWN

As of Apr 22, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Day One Biopharmaceuticals, Inc. (DAWN) on higher Unified Composite conviction (50.4/100 HOLD vs. 58.3/100 HOLD) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while DAWN wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus DAWN at $21.53 (N/M Forward P/E, -51.1% operating margin).

  • Composite vs. Pillar Nuance: While DAWN currently prints a higher short-term Unified Composite Score (58.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51.1% operating margin) and revenue trajectory (+0.0% vs. +83.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs DAWN
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
DAWN NASDAQ
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
TTM Revenue $158M
Forward P/E N/M
Beta / 30D Vol 0.03β · 2% Vol
Unified Composite Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 80
RSI-14: 80.5 · SMA20: $21.45 · SMA50: $18.01

6-Pillar Scorecard Institutional Category Breakdown (VTYX 2 – 3 DAWN)

Columns: Metric · VTYX · DAWN
1. Valuation Multiples DAWN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 14.0x
2. Growth & Scale DAWN
Revenue Growth (YoY) +0.0% +83.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $158M
Market Cap $1.0B $2.2B
3. Profitability & Quality VTYX
Gross Margin N/A 89.1%
Operating Margin 0.0% -51.1%
Net Profit Margin 0.0% -67.8%
Return on Equity (ROE) -45.4% -22.7%
4. Balance Sheet & Cash Flow DAWN
Cash Generation (TTM) N/A -$124M EBITDA
Cash Flow Margin N/A -78.6% EBITDA Mgn
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $4.28 Book/Sh · -22.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.5% (<1st %ile) 0.6% (<1st %ile)
Put/Call OI Skew N/A 0.45x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (2) vs DAWN (6)
Institutional Metric VTYX DAWN Criterion Row Edge
Market Capitalization
Scale
$1.0B $2.2B Larger Scale DAWN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +83.9% Higher Growth DAWN
Operating Margin (TTM)
Profitability
0.0% -51.1% Higher Margin VTYX
Net Profit Margin
Profitability
0.0% -67.8% Higher Margin VTYX
Return on Equity (ROE)
Capital Efficiency
-45.4% -22.7% Higher ROE DAWN
52-Week Range Position
Momentum
55% ($1–$25) 100% ($6–$22) Stronger Trend DAWN
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 0.03β · 2% Vol Lower Realized Risk DAWN
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 58.3 / 100 (HOLD) Higher Composite DAWN
Trailing 12M Revenue (USD)
Operating Scale
N/A $158M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 89.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) -$124M EBITDA ($4.28 Book/Sh · -22.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +10.49 pp
VTYX: +0.36% · DAWN: -10.13%
3M Horizon VTYX +34.31 pp
VTYX: +40.0% · DAWN: +5.69%
6M Horizon VTYX +449.77 pp
VTYX: +483.33% · DAWN: +33.56%
1Y Horizon VTYX +1098.46 pp
VTYX: +1138.94% · DAWN: +40.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs DAWN. Trailing 12-month operating profitability (VTYX 0.0% vs DAWN -51.1%) and valuation multiples (VTYX N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
DAWN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158M
Gross Margin89.1%
Op. Margin-51.1%
ROE / Fwd P/E-22.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DAWN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact DAWN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DAWN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs DAWN Key Questions & Quantitative Answers

As of Apr 22, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Day One Biopharmaceuticals, Inc. (DAWN) on higher Unified Composite conviction (50.4/100 HOLD vs. 58.3/100 HOLD) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while DAWN wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus DAWN at $21.53 (N/M Forward P/E, -51.1% operating margin). Composite vs. Pillar Nuance: While DAWN currently prints a higher short-term Unified Composite Score (58.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51.1% operating margin) and revenue trajectory (+0.0% vs. +83.9% YoY).

DAWN leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DAWN at +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $158M for DAWN. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAWN.

DAWN screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus DAWN (-22.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 22, 2026. For educational research only; not investment advice.